Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection - an update of the literature

References

• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–1100.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis Am. 2010;50:1101–1111.
   PubMed Web of Science ®Google Scholar
• Atılgan A O, Özdemir BH, Kırnap M, et al. Invasive fungal infections in liver transplant recipients. Exp Clin Transplant. 2014;12 Suppl 1:110–116.
   PubMed Web of Science ®Google Scholar
• Liu Y-C, Chien S-H, Fan N-W, et al. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect. 2016;49:567–574.
   PubMedGoogle Scholar
• Herrera S, Davoudi S, Farooq A, et al. Late onset invasive pulmonary Aspergillosis in lung transplant recipients in the setting of a targeted prophylaxis/preemptive antifungal therapy strategy. Transplantation. 2020;104:2575–2581.
   PubMedGoogle Scholar
• Shekar M, Elumalai R, Elayaperumal I, et al. Prevalence and outcome of systemic fungal infections in renal transplant recipients - A tertiary care experience. Saudi J kidney Dis Transplant. 2019;30:1137–1143.
   PubMed Web of Science ®Google Scholar
• Valencia Y, Cáceres DH, de Bedout C, et al. Frequency of Invasive Fungal Disease in Adults: experience of a Specialized Laboratory in Medellín, Colombia (2009-2015). J Fungi (Basel, Switzerland). 2020;6:39.
   Google Scholar
• Lum L, Lee A, Vu M, et al. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. Transpl Infect Dis. 2020;22:e13361.
   PubMedGoogle Scholar
• Kazakou N, Vyzantiadis TA, Gambeta A, et al. Invasive fungal infections in a pediatric hematology-oncology department: a 16-year retrospective study. Curr Med Mycol. 2020;6:37–42.
   PubMedGoogle Scholar
• Itsaradisaikul S, Pakakasama S, and Boonsathorn S, et al. Invasive fungal disease among pediatric and adolescent patients undergoing itraconazole prophylaxis after hematopoietic stem cell transplantation. Transplant Proc 2021;53(6):2021–2028.
   PubMed Web of Science ®Google Scholar
• Santos T, Aguiar B, Santos L, et al. Invasive fungal infections after kidney transplantation: a single-center experience. Transplant Proc. 2015;47:971–975.
   PubMed Web of Science ®Google Scholar
• Klingspor L, Saaedi B, Ljungman P, et al. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Mycoses. 2015;58:470–477.
   PubMed Web of Science ®Google Scholar
• Kabbani D, Goldraich L, and Ross H, et al. Outbreak of invasive aspergillosis in heart transplant recipients: the role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis. Transpl Infect Dis. 2018;20(1): e12808.
   Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Harrington R, et al. Epidemiology and outcomes of hospitalizations with invasive Aspergillosis in the United States, 2009-2013. Clin Infect Dis 2018;67:727–735.
   PubMed Web of Science ®Google Scholar
• Lien M-Y, Chou C-H, Lin -C-C, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study. PLoS One. 2018;13:e0197851.
   PubMed Web of Science ®Google Scholar
• Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016. BMC Infect Dis. 2019;19:274.
   PubMed Web of Science ®Google Scholar
• Fracchiolla NS, Sciumè M, Orofino N, et al. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: results from a single-centre study. PLoS One. 2019;14:e0216715.
   PubMed Web of Science ®Google Scholar
• Linke C, Ehlert K, Ahlmann M, et al. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. Mycoses. 2020;63:172–180.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• Alanio A, Dellière S, Fodil S, et al. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48–e49.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Rijnders BJA, Brüggemann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46:1524–1535.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2021;73:e3606–e3614.
   PubMed Web of Science ®Google Scholar
• Marr KA, Platt A, Tornheim JA, et al. Aspergillosis Complicating Severe Coronavirus Disease. Emerg Infect Dis. 2021;27:18–25.
   Web of Science ®Google Scholar
• Machado M, Valerio M, Álvarez-Uría A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses. 2021;64:132–143.
   PubMed Web of Science ®Google Scholar
• Permpalung N, Chiang TP-Y, Massie AB, et al. COVID-19 associated pulmonary Aspergillosis in mechanically ventilated patients. Clin Infect Dis. 2022;74:83–91.
   PubMedGoogle Scholar
• Jenks JD, Nam HH, Hoenigl M. Invasive aspergillosis in critically ill patients: review of definitions and diagnostic approaches. Mycoses. 2021;64:1002–1014.
   PubMed Web of Science ®Google Scholar
• Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49 Suppl 1:S7–S12.
   PubMed Web of Science ®Google Scholar
• Blot SI, Taccone FS, Van Denabeele A, et al. A clinical algorithm to diagnose invasive pulmonary Aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64.
   PubMed Web of Science ®Google Scholar
• Meis JF, Chowdhary A, and Rhodes JL, et al. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc London Ser B Biol Sci. 2016;371:1709.
   Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJG, et al. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal Azoles? Clin Infect Dis 2016;62:362–368.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Isavuconazonium: first global approval. Drugs. 2015;75:817–822.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Maher R, Hope WW. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Rev Clin Pharmacol. 2016;9:887–897.
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Moradi PW, et al. Pharmacokinetics and concentration-dependent efficacy of Isavuconazole for treatment of experimental invasive pulmonary Aspergillosis. Antimicrob Agents Chemother. 2016;60:2718–2726.
   PubMed Web of Science ®Google Scholar
• Desai A, Kovanda L, Kowalski D, et al. Population pharmacokinetics of Isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483–5491.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769. **Key trial showing the efficacy of ISZ for management of IA.
   PubMed Web of Science ®Google Scholar
• Kaindl T, Andes D, Engelhardt M, et al. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019;74:761–767.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Desai AV, Lu Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (Results from the VITAL Study). Antimicrob Agents Chemother. 2016;60:4568–4576.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma U. Prescribing Information for Isavuconazonium Sulfate. [cited 4 10 2021]. Available from: https://www.astellas.us/docs/cresemba.pdf
   Google Scholar
• Rudramurthy SM, Chakrabarti A, Geertsen E, et al. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis. 2011;71:370–377.
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lechner V, Lass-Flörl C. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53:1645–1647.
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006;57:135–138.
   PubMed Web of Science ®Google Scholar
• Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–1400.
   PubMed Web of Science ®Google Scholar
• Schwarz P, Djenontin E, Dannaoui E. Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus Niger. Microorganisms. 2020;8:1447.
   Web of Science ®Google Scholar
• Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother. 2006;58:1198–1207.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A-H, Kato K, Townsend R, et al. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of Isavuconazonium Sulfate to rats. Antimicrob Agents Chemother. 2017;61:e01292–17.
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of Isavuconazole with Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6:44–53.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Desai A, Han D, et al. Pharmacokinetic interaction between Isavuconazole and a fixed-dose combination of Lopinavir 400 mg/Ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6:93–101.
   PubMed Web of Science ®Google Scholar
• Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of Isavuconazole with the immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6:76–85.
   PubMed Web of Science ®Google Scholar
• Niazi-Ali S, Atherton GT, Walczak M, et al. Drug-drug interaction database for safe prescribing of systemic antifungal agents. Ther Adv Infect Dis. 2021;8:20499361211010604.
   Google Scholar
• DiPippo AJ, and Kontoyiannis DP. Lack of toxicity with long-term Isavuconazole use in patients with hematologic malignancy. Clin Infect Dis an off Publ Infect Dis Soc Am. 2019;69:1624–1627••Key study showing lack of toxicty with long term use of ISZ.
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses. 2019;62:81–86.
   PubMed Web of Science ®Google Scholar
• Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transplant. 2016;30:1377–1386.
   PubMed Web of Science ®Google Scholar
• Andes D, Kovanda L, Desai A, et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob Agents Chemother. 2018;62:e00585–18.
   PubMed Web of Science ®Google Scholar
• Borman AM, Hughes JM, Oliver D, et al. Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center. Med Mycol. 2020;58:996–999.
   PubMed Web of Science ®Google Scholar
• Risum M, Vestergaard M-B, and Weinreich UM, et al. Therapeutic drug monitoring of Isavuconazole: serum concentration variability and success rates for reaching target in comparison with Voriconazole. Antibiot (Basel, Switzerland). 2021;10(5): 487.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Busca A, Gramegna D, et al. Isavuconazole in hematological patients: results of a real-life multicentre observational Seifem study. HemaSphere. 2019;3:e320.
   PubMed Web of Science ®Google Scholar
• Van Matre ET, Evans SL, Mueller SW, et al. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Ann Clin Microbiol Antimicrob. 2019;18:13.
   PubMed Web of Science ®Google Scholar
• Hassouna H, Athans V, and Brizendine KD. Real-world use-Isavuconazole at a large academic medical center. Mycoses. 2019;62:534–541.
   PubMed Web of Science ®Google Scholar
• Vu CA, Rana MM, Jacobs SE, et al. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transpl Infect Dis. 2021;23:e13469.
   PubMed Web of Science ®Google Scholar
• Decembrino N, Perruccio K, and Zecca M, et al. A case series and literature review of Isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2020;64(3): e01783–19.
   PubMed Web of Science ®Google Scholar
• Oarbeascoa G, Dorado N, and Bailén R, et al. Successful treatment of severe Aspergillosis with Isavuconazole therapy after allogeneic stem cell transplantation. Chemother Switzerland. 2019;64(2) :57–61.
   PubMed Web of Science ®Google Scholar
• Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. Antimicrob Agents Chemother. 2021;65:e0029021.
   PubMed Web of Science ®Google Scholar
• Bagshaw E, Enoch DA, Blackney M, et al. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiol. 2018;13:1283–1293.
   PubMed Web of Science ®Google Scholar
• Azanza JR, Grau S, Vázquez L, et al. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses. 2021;64:66–77.
   PubMed Web of Science ®Google Scholar
• Floros L, Pagliuca A, Al TA, et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. J Med Econ. 2020;23:86–97.
   PubMed Web of Science ®Google Scholar
• Harrington R, Lee E, Yang H, et al. Cost-effectiveness analysis of Isavuconazole vs. Voriconazole as first-line treatment for invasive Aspergillosis. Adv Ther. 2017;34:207–220.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020;58:417–424.
   PubMed Web of Science ®Google Scholar
• Zurl C, Waller M, Schwameis F, et al. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of Isavuconazole plasma concentrations. J Fungi (Basel, Switzerland). 2020;6:90.
   Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–e162.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough Invasive fungal infections on Isavuconazole prophylaxis and treatment: what is happening in the real-world setting?. Clin Infect Dis. 2018;67:1142–1143.
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiPippo AJ, Bose P, et al. Breakthrough fungal infections in patients with leukemia receiving Isavuconazole. Clin Infect Dis. 2018;67:1610–1613.
   PubMed Web of Science ®Google Scholar
• Fontana L, Perlin DS, and Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70:723–730.
   PubMed Web of Science ®Google Scholar
• Bogler Y, Stern A, and Su Y, et al. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59(10): 970–979.
   PubMed Web of Science ®Google Scholar
• Salas MQ, Mussetti A, and Muñóz C, et al. Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: a single-center experience. Hematol Transfus Cell Ther Brazil. 2021;S2531-1379(21): 00024–9.
   Google Scholar
• Stern A, Su Y, Lee YJ, et al. A single-center, open-label trial of Isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:1195–1202.
   PubMed Web of Science ®Google Scholar
• Bowen CD, Tallman GB, Hakki M, et al. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: initial experience at an academic medical centre. Mycoses. 2019;62:665–672.
   PubMed Web of Science ®Google Scholar
• Bose P, McCue D, and Wurster S, et al. Isavuconazole as primary antifungal prophylaxis in patients with Acute Myeloid Leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study. Clin Infect Dis 2021;72:1755–1763 .
   PubMed Web of Science ®Google Scholar
• Chen P, Liu J, Zeng M, et al. Exploring the molecular mechanism of azole resistance in Aspergillus fumigatus. J Mycol Med. 2020;30:100915.
   PubMed Web of Science ®Google Scholar
• Jørgensen KM, Astvad KMT, and Hare RK, et al. EUCAST susceptibility testing of Isavuconazole: MIC data for contemporary clinical mold and yeast isolates. Antimicrob Agents Chemother. 2019;63(6): e00073–19.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kathuria S, Randhawa HS, et al. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67:362–366.
   PubMed Web of Science ®Google Scholar
• Pasula S, Chandrasekar PH. Azole resistance in Aspergillus species: promising therapeutic options. Expert Opin Pharmacother. 2021;22:2071–2078.
   PubMed Web of Science ®Google Scholar